While receptor tyrosine kinase (RTK) signaling pathways including MET are among the most common dysregulated pathways in human gliomas, oncogenic activation of MET due to alterations including MET exon 14 skipping or PTPRZ1::MET fusion appear significantly enriched in secondary glioblastoma in adult cohorts [15, 16]. This evidence concerns the gene MET and central nervous system cancer.